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Mouse models have increased our understanding of the pathogenesis of medulloblastoma (MB), the most
common malignant pediatric brain tumor that often forms in the cerebellum. A major goal of ongoing research is
to better understand the early stages of tumorigenesis and to establish the genetic and environmental changes
that underlie MB initiation and growth. However, studies of MB progression in mouse models are difficult due to
the heterogeneity of tumor onset times and growth patterns and the lack of clinical symptoms at early stages.
Magnetic resonance imaging (MRI) is critical for noninvasive, longitudinal, three-dimensional (3D) brain tumor
imaging in the clinic but is limited in resolution and sensitivity for imaging early MBs in mice. In this study, high-
resolution (100 μm in 2 hours) and high-throughput (150 μm in 15 minutes) manganese-enhanced MRI (MEMRI)
protocols were optimized for early detection and monitoring of MBs in a Patched-1 (Ptch1) conditional knockout
(CKO) model. The high tissue contrast obtained with MEMRI revealed detailed cerebellar morphology and enabled
detection of MBs over a wide range of stages including pretumoral lesions as early as 2 to 3 weeks postnatal with
volumes close to 0.1 mm3. Furthermore, longitudinal MEMRI allowed noninvasive monitoring of tumors and
demonstrated that lesions within and between individuals have different tumorigenic potentials. 3D volumetric
studies allowed quantitative analysis of MB tumor morphology and growth rates in individual Ptch1-CKO mice.
These results show that MEMRI provides a powerful method for early in vivo detection and longitudinal imaging of
MB progression in the mouse brain.
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Pediatric central nervous system tumors are the leading cause of
cancer-related mortality in childhood. In this age group, medullo-
blastoma (MB) is the most frequent malignant brain tumor
accounting for approximately 20% of all cases. MB is an embryonal
tumor found in the cerebellum (Cb) that typically appears between
the ages of three and nine but is also found in infants and adults [1,2].
With advances in aggressive treatment strategies combining surgery,
cranio-spinal radiotherapy (in children ≥3 years of age), and
chemotherapy, overall survival rates for patients with MB approaches
70% to 80% [3–5]. In spite of this progress in patient outcome,
clinical management of MB still remains a challenge since patients
who do survive often suffer devastating effects of the multimodal
therapy, such as major long-term neurocognitive and neuroendocrine
sequelae and a significant risk of developing secondary tumors [6–9].
For this reason, characterization of MB pathogenesis is the focus of
intense research in neuro-oncology, with the hope that a greater
understanding of the biologic pathways disrupted in this disease will
lead to the development of novel and less harmful therapies
specifically targeted to the abnormal molecular signatures of this
developmental cerebellar tumor.
Significant progress has been made in our understanding of the
pathogenesis of MB as a result of genome-wide profiling of humanMB
samples [10–12]. There is now clear evidence that MB is not a single
tumor entity but that it comprises at least four subgroups, including
those related to mutations in theWingless and Sonic Hedgehog (SHH)
signaling pathways, each associated with distinct gene expression
signatures, transcriptomes, histopathologic phenotypes, and prognoses
[13,14]. Furthermore, mouse models have been reported relevant to all
four known MB subgroups [3,15–20]. From both the clinical and
preclinical studies, consensus is forming that identification of the
subgroup status and further subclassification [21] of these subgroups
will enable treatment strategies tailored to individual tumors, which
should translate into improved patient outcomes.
Despite this progress, detailed understanding of the differences
between these MB subgroups and the degree of heterogeneity that exists
within and between subgroups is still unclear. For example, the SHH-MB
subgroup, consisting of approximately 30% of humanMBs, is one of the
most studied subtypes and has been recapitulated in several geneticmouse
models [3,15] and was recently subdivided into three human subtypes
[21]. SHH is an essential pathway that normally regulates the
proliferation of one of the major cell populations within the developing
Cb, the granule cell precursors (GCPs) [22,23]. Several studies have
demonstrated a connection between increased SHH signaling and MB
tumorigenesis, most notably due to loss-of-function mutations in
Patched-1 (Ptch1) [24–26] and activating mutations in Smoothened
[27,28], the two key receptors of the pathway. Likewise, it has been
substantially shown that GCPs are susceptible to malignant transforma-
tion and subsequent MB formation through oncogenic activation of the
SHHpathway, revealingGCPs as the primary cell of origin of SHH-MBs
[29,30]. Interestingly, there is emerging clinical evidence of complex
molecular heterogeneity within MBs, including within this well-
characterized SHH subgroup [21,31–35], which could indicate distinct
cellular etiologies, specific altered signaling pathways, or differences in the
timing and location of the cells of origin and genetic mutations driving
tumor formation and progression. Therefore, it seems likely that
additional uncharacterized MB subgroupings could be present and that
additional large human and preclinical studies are needed to further
dissect their biologic basis and degree of clinical relevance.Given the importance of mouse models in this research, there is a
clear need for efficient, high-throughput methods for analyzing MB
phenotypes. Analysis of current mouse MB models has been mostly
limited to static, two-dimensional (2D) information acquired with
traditional histologic methods. Complementing these data, in vivo
imaging modalities should provide a powerful approach for
noninvasive tumor detection in mouse models, which are often
limited by incomplete penetrance. Additionally, sensitive imaging
techniques could allow the characterization and monitoring of tumor
progression and the volumetric quantification of changes in response
to novel therapies. In particular, detection and analysis of the early
stages of tumorigenesis is especially important for brain tumors like
MB, given that early stages of disease are asymptomatic and advanced-
stage tumors may not accurately reflect the most relevant initiating or
driver mutations for tumor progression.
Due to its excellent tissue contrast and high penetration and
resolution, clinical magnetic resonance imaging (MRI) has played a
major role in the diagnosis and management of human brain tumors.
However, there are certain challenges for the use of MRI in preclinical
brain tumor research. For instance, the utility of in vivo MRI in
mouse tumor systems relies on the development of imaging protocols
for high-throughput screening in models that traditionally have been
limited by incomplete penetrance, as well as high-resolution in vivo
analysis even at the early tumor stages. In addition, the establishment
of MRI protocols for longitudinal imaging over extended periods of
time is crucial for dynamic qualitative and quantitative analysis of
tumor progression, which should provide a better stratification of
experimental cohorts based on tumor phenotype and behavior.
Previous studies have used conventional MRI techniques for
morphologic brain tumor imaging in mouse MB models, but similar
to most human studies [36–39], mouse MB MRI reports have largely
focused on detection and monitoring of tumor burden at relatively
advanced tumor stages. For example, T2-weighted (T2w) MRI has
been used to define the location and extent of advanced MBs in
mouse models [40–42], while gadolinium-enhanced T1-weighted
(T1w) imaging has been used to evaluate breakdown of the blood-
brain barrier (BBB) and leakage of the contrast agent into MB tumors
[40]. Because gadolinium enhancement depends on tumor type and
stage and is often observed at later stages of tumor progression,
gadolinium-enhanced imaging has not been used extensively for early
tumor detection in the clinic, especially for MB.
The overall goal of the current study was to implement an in vivo
MRI protocol for early detection and characterization of tumor
progression in a mouse model of SHH-MB. Manganese (Mn)–
enhanced MRI (MEMRI) has been used extensively for both anatomic
and functional neuroimaging studies in mice. MEMRI relies on the
properties of paramagneticMn2+ ions to produceMR contrast. Besides
multiple roles in normal physiology, Mn2+ can function as a calcium
(Ca2+) analog, entering neurons through voltage-gated Ca2+ channels
and resulting in positive enhancement onT1wMR images of the tissues
where it accumulates. Once in neurons, Mn2+ is also transported
along axons and can cross synapses to accumulate in adjacent
neurons [43–48]. We have previously demonstrated the utility of
MEMRI for detailed analysis of brain and Cb development in normal
and mutant mice, from embryonic to adult stages [49–54]. Given the
increased signal and high degree of anatomic definition in the Cb
obtained with MEMRI [53], we reasoned that this would be a good
potential method for analyzing abnormalities in cerebellar anatomy
caused by the presence of MB lesions.
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to apply and optimize an in vivoMEMRI protocol for the detection and
high-resolution imaging of early stages of MB tumorigenesis in Ptch1–
conditional knockout (CKO)mice, a model of the SHH-MB subgroup
that arises from very few Ptch1 mutant GCPs. Second, we sought to
implement a time-efficient MRI protocol for high-throughput
screening of tumor presence in Ptch1-CKO mice. Third, we aimed to
use these protocols for longitudinal imaging and volumetric analysis of
MB growth patterns to noninvasively characterize the progression of
individual MB lesions from early to advanced stages.
Methods
Animals
All mice used in this study were maintained under protocols
approved by the Institutional Animal Care and Use Committee at New
York University School of Medicine. Ptch1-CKO mice (Ptf1aCre/+;
Ptch1fl/fl) were generated by mating Ptf1aCre/+ mice [55], which were
also heterozygous for a floxed allele of the Ptch1 gene (Ptch1fll+), with
homozygous Ptch1fl/fl mice [56]. The genotype of each mouse was
confirmed by polymerase chain reaction of tail biopsy, using primers for
Ptch1[56] and Cre [57]. For MEMRI, a 30 mM MnCl2 solution of
manganese chloride tetrahydrate (Sigma-Aldrich-221279) in isotonic
saline was injected intraperitoneally (IP) 24 hours before imaging, at a
dose per weight of 0.4 or 0.5 mmol/kg (50 and 62.5 mgMnCl2 per kg
body weight for mice aged 3 weeks or less and 1 month or more,
respectively). This dose corresponded to a single IP injection of 0.4 to
0.5ml ofMnCl2 solution per 30-gmouse. ThisMnCl2 dose was similar
to the dose documented in the previous work using MEMRI for brain
imaging [49,53,54,58]. At this dose, no obvious adverse effects were
noticed as a consequence of MnCl2 administration in this study.
Mouse Brain MRI
MRIwas performed in a 7-Tesla, 200-mm diameter horizontal bore
magnet (Magnex Scientific, Yarnton, United Kingdom) interfaced to a
Bruker Biospec Avance II console (Bruker BioSpin MRI, Ettlingen,
Germany) with actively shielded gradients (750 mT/m; BGA9S;
Bruker) and using a 25-mm (inner diameter) quadrature Litz coil
(Doty Scientific, Columbia, SC). For each imaging session, mice were
anesthetized with isoflurane (5% in air for initial induction followed
by 1.0-1.5% in air delivered through nosecone during imaging) and
placed in mouse holders [59] (Dazai Research Instruments, Toronto,
Ontario) that secured the body and head to facilitate reproducible
setup and to minimize motion artifacts. Physiological body
temperature was maintained using a warm air system, and respiration
and heart rates were monitored using MR compatible equipment
(SAII; SA Instruments, Stony Brook, NY). In vivo MRI images were
obtained using a three-dimensional (3D) T1w gradient echo
sequence for high-throughput screening [echo/repetition times
(TE/TR) = 4/15 ms; flip angle (FA) = 18°; field of view = 19.2 mm ×
19.2mm×12mm;matrix = 128 ×128 × 80, providing 150-μmisotropic
resolution in approximately 15 minutes] and/or a higher-resolution 3D
T1w gradient echo self-gated sequence [60] to minimize motion artifacts
(TE/TR = 3.6/50 ms; FA = 40°; field of view = 25.6 mm × 25.6 mm ×
25.6 mm; matrix = 256 × 256 × 256, providing 100-μm isotropic
resolution in 1 hour and 49 minutes). Selected mice were also
scanned with a 2D multislice T2w fast spin echo “Rapid
Acquisition with Refocused Echoes” (RARE) sequence (TE/TR =
8.9/4000 ms; effective TE = 35 ms; number of averages = 4; six0.5-mm 2D slices; 2D matrix = 256 × 256, providing 80-μm in-
plane resolution in approximately 9 minutes).
MRI Analysis
After reconstruction, MRI images were analyzed using AMIRA
Imaging software (V5.2; Visage Imaging, San Diego, CA). Data sets
were oriented to allow visualization of axial, sagittal and coronal
planes through the brain. For quantitative analysis, volumetric
measurements and 3D renderings were generated from MEMRI
images using a combination of manual and semi-automated
segmentation tools as previously reported [51,53,61]. Whole brain,
Cb, and tumor regions were delineated and a mask was created for
each area. Once the masks of the entire regions were obtained and
corrected, they were represented three-dimensionally using the
Surface Rendering modules in AMIRA. For quantification purposes,
the total volume from the segmented and rendered regions (in voxels)
was measured using the AMIRA Tissue Statistics function and
converted to mm3. As previously described, MEMRI images had
excellent contrast and allowed detailed visualization of normal
cerebellar anatomy [49,53,58]. In our study, advanced tumors and
early pretumoral lesions were visualized as non-enhanced areas of
negative contrast within the enhanced layers of the cerebellar folia.
Consequently, tumor tissue was identified, segmented, and manually
refined for every section while comparing to normal mouse brain
anatomy at the different imaging planes using MEMRI images of
control littermates. Segmentations of selected tumors were correlated
with histology at each stage to validate the MEMRI results. To
compare the difference in MRI detection and volumetric measure-
ments between the high-resolution 100-μm and high-throughput
150-μm sequences, we selected a group of mice at 3 weeks and
scanned them sequentially with both MEMRI protocols. We then
independently segmented the early pretumoral lesions visible in each
MEMRI sequence and calculated their volumes with AMIRA. Using
the statistical analysis software OriginPro 7.5 (OriginLab Corp,
Northampton, MA), we performed a two-sample paired t test to
investigate the difference between the two MRI protocols for each
tumor volume measurement at the P b .05 level of confidence.
Tumor Growth Analysis
To quantify tumor growth characteristics, longitudinal MEMRI
images of individual animals were obtained and volumes were
calculated according to the protocol described above. Each individual
Ptch1-CKO mouse had three to seven longitudinal scans between 3
and 26 weeks of age, and the imaging time points were separated by at
least 2 weeks. For each mouse, the tumor volume was fitted to an
exponential growth model:
Volume ¼ V 0  ebt ; ð1Þ
where t is the time in weeks, V0 is the initial volume (extrapolated
back to t = 0), and the exponent b is converted to the tumor doubling
time (Td) in weeks [62] using the following formula:
Td ¼ ln 2ð Þ=b: ð2Þ
The correlation coefficient R2 was computed for each exponential
fit. For comparison between individuals, each growth curve was
normalized to its initial volume (V0), and the normalized curves were
displayed on a semi-logarithmic plot.
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For histologic analyses, mice were perfused transcardially with 4°C
phosphate-buffered saline (PBS)mixedwithheparin (5000heparin units/l),
followed by 4°C 4% paraformaldehyde. After perfusion, brains were
dissected and post-fixed with 4% paraformaldehyde at room temper-
ature for 2 hours. Tissuewas then processed for paraffin embedding, and
10-μm sagittal sections were acquired, covering the entire Cb and tumor
of each mouse. Normal Cb and MB tumors were examined using
hematoxylin and eosin (H&E) staining and immunohistochemistry
(IHC) with heat antigen retrieval in citric acid buffer (pH = 6).
For IHC, the primary antibodies used were rabbit anti-Ki67 (1:500;
Abcam ab15580) and mouse anti-p27 (1:1000, BD Biosciences
610241), followed by anti-rabbit Alexa Fluor 555 (1:1000) and anti-
mouse Alexa Fluor 488 (1:1000) for secondary antibody staining. Slideswere
counterstained with Hoechst or 4′6-diamidino-2-phenylindole (DAPI) for
nuclear visualization and imaged on an inverted microscope (Zeiss Axio
Observer.A1 microscope with Axiovision software). IHC for Ki67 was also
visualized in selected slides using streptavidin-HRPconjugate, developedwith
DAB and counterstained with hematoxylin. After staining, slides were
coverslipped and imaged using a bright-fieldmicroscope (Nikon Eclipse
E400) or a digital slide scanner (Leica SCN400F).
For some slides, Ki67/p27 staining was combined with Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining to assess apoptosis. For this, sections were permeabilized with
0.5% Triton X-100 in PBS for 10 minutes, washed with PBS, and
preincubated for 15 minutes with TdT buffer 1× supplemented with 1
mM CoCl2. Terminal transferase (Roche Product No. 03333566001)
and Biotin-16-dUTP (Roche Product No. 11093070910) were added,
and the reaction was carried out as recommended by the manufacturer
on sections for 1 hour at 37°C and the reaction was stopped with 0.01%
Tween 20 in PBS. Signal was revealed by streptavidin-conjugated to
Alexa Fluor 647, diluted 1:500 in PBS.
Captured images were analyzed using Adobe Photoshop and
SlidePath Digital Image Hub (Leica Biosystems, Buffalo Grove, IL).
For analysis of tumor differentiation (using Ki67/p27 staining), two to
three slides per tumor (containing both lateral andmedial sections) were
examined and qualitatively assessed for the presence of differentiated
regions in five to ten images per slide at both ×10 and ×20
magnification. For semi-quantitative analysis, we acquired representa-
tive 10× images covering the entire tumor region in each slide (15-35
images per tumor depending on tumor size) and determined the
fraction of images that showed isolated regions of differentiation for
each tumor: (−) for 0 to 5%, (+) for 5% to 25%, (++) for 25% to 50%,
and (+++) for N50%.Results
In vivo MEMRI Allowed Noninvasive Detection of MB
Tumors in Ptch1-CKO Mice
As demonstrated previously [49,53], in vivoMEMRI images showed
region-specific signal and contrast enhancement in the mouse brain and
allowed more detailed visualization of normal Cb morphology when
compared to a non-MEMRI image (Figure 1, A and B). Abnormal Cb
lesions were detected and easily delineated as hypointense regions
within the enhanced Cb (Figure 1, C–E) in 74 of 92 Ptch1-CKO mice
imaged with MEMRI between 11 and 28 weeks of age (80%). In
selected Ptch1-CKO mice with MBs, gadolinium-enhanced T1w MRI
showed heterogeneous patterns of enhancement similar to reports in
other mouse MB models [40], which was not useful for delineating thelesion margins (Supplemental Fig. 1). Within the group of 74 lesion-
bearing Ptch1-CKO mice imaged with MEMRI between 11 and 28
weeks of age, 47 mice presented symptoms commonly observed in
advanced Cb tumors including weight loss, domed head, hunched
posture, and ataxia at the time of sacrifice.
On MEMRI, symptomatic mice typically had either unilateral
focal (N = 36/47) or bilateral widespread (N = 11/47) hypointense
tumors, primarily located within the anterior regions of the Cb
hemispheres. These advanced-stage tumors measured 112.2 ± 92.0
mm3 in volume (N = 47, mean ± SD) and generally showed
displacement of midline structures together with variable degrees of
hydrocephalus (Figure 1, C and D). Histopathologic analysis
confirmed that regions of negative contrast in MEMRI images
correlated to MB tumor tissue in matched H&E-stained sections
(Figure 1, E and F ). In asymptomatic mice beyond 11 weeks of age
(N = 27/74), MEMRI also identified mice with intermediate-sized
tumors (N = 18/27, 23.5 ± 11.5 mm3) or small focal Cb lesions (N =
9/27, 5.4 ± 2.0 mm3). Quantitative analysis of the volume of tumors
and brain ventricles showed large variability in tumor size and degree of
hydrocephalus between symptomatic mice in the same age groups
(Supplemental Table 1; N = 47). These results suggest variability in
tumor onset time and/or growth rates in the Ptch1-CKO mice, similar
to other mouse MB models [3]. The obvious challenges of studying
tumor biology based on age or clinical symptoms highlight the need for
noninvasive imagingmethods to detect andmonitor tumor progression.In vivo MEMRI Enabled Characterization of the Early Stages
of MB Formation
To investigate early stages of MB formation, high-resolution
(100-μm) in vivo MEMRI images were obtained from postnatal day
14 (P14) and P21 wild-type (N = 10) and Ptch1-CKO (N = 16) mice
(Figure 2). At these early time points, Ptch1-CKO mice were observed
to preserve the overall normal foliation pattern; however, abnormal
hypointense areas, 100 to 200 μm or more in thickness, were detected
on the surface of the Cb of Ptch1-CKO mice, often between the folia
(Figure 2, A–D). Matching histologic sections with MEMRI images
from individual mice (N = 12) showed excellent qualitative agreement and
confirmed these hypointense areas as regions of hyperplasia and persistence
of the P14 to P21 external granule cell layer, the proliferative zone of
the postnatal Cb that is normally depleted by P16 (Figure 2,C–F ). These
regions of persistent external granule cell layer, observed as hypointense
areas on MEMRI, are referred to as “pretumoral lesions” in this paper.
3D renderings were generated from MEMRI images to examine the
morphology, spatial distribution, and volume of histologically validated
early pretumoral lesions at P14 to P21 (Figure 2G). The average lesion
volume at P14 to P21 was 6.70 ± 3.31 mm3, and three distinct
phenotypes were observed: (1) unilateral lesion (N = 2/12), (2) bilateral
lesion that appeared to be connected (N = 6/12), and (3) multiple
separated lesions (N = 4/12; Supplemental Video 1). All of the lesions
had a predominant anterior component (N = 12), while many also had a
smaller posterior component (N = 8/12), using lobule VIb in the vermis
and crus I in the hemispheres as the reference structures dividing
anterior from posterior.
MEMRI Is More Sensitive for the Detection of Early
Pretumoral MB Lesions than Conventional MRI
Accurate detection of early stages of tumor formation is critical for
enhancing the value of MRI in preclinical studies. Conventional MRI
of brain tumors typically uses T2w images for assessing tumor
Figure 1. In vivoMEMRI detection of MB tumors in Ptch1-CKO mice. Compared to non–Mn-enhanced T1w MRI (A), post-contrast signal
enhancement in axial MEMRI image (B) enabled visualization of normal brain and Cb anatomy in wild-type mice. MEMRI also allowed
detection of advanced MB tumors as hypointense areas (*) within the Cb of Ptch1-CKO mice, typically located in the Cb hemispheres
(C and D), and demonstrated severely enlarged ventricles (V) in somemice (D). Panel E shows a sagittal section from the mouse shown in
C (dashed line indicates the approximate location of the section) and highlights theMB tumor (*). Amatched histologic section (F), stained
with H&E, showed good correlation of tumor location with MEMRI (E). Scale bars, 1 mm for A to F (scale on D for A–D).
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T2w RARE images were acquired in the same Ptch1-CKO mice to
assess the sensitivity of each protocol to detect MB lesions at distinct
stages of tumor formation. As previously described, tumor tissue and
areas of hydrocephalus showed low signal intensity on T1w MEMRI,
whereas these regions showed high signal intensity on T2w RARE
images (Figure 3). At late stages (11-28 weeks old, N = 9), severe
brain deformity and large tumors were successfully detected in both
types of images; however, the Cb foliation pattern and the tumor
margins were better demarcated with MEMRI (Figure 3, A–D). At
early stages (P14-P21, N = 9), hypointense pretumoral lesions
surrounded by enhanced cerebellar folia were clearly visible on
MEMRI, while the majority of those same lesions were undetectable
on RARE due to the lack of contrast between tumor and normal Cb
(Figure 3, E–H ). Specifically, a total of 24 distinct pretumoral lesions
was visualized with MEMRI in the group of P14 to P21 Ptch1-CKO
mice (N = 9), but only 4 of 24 (17%) of those early pretumoral lesionswere also detected with RARE. Volumetric analysis based onMEMRI
data revealed that the average size of the early pretumoral lesions
detectable with both MEMRI and RARE was 3.10 ± 1.14 mm3
(minimum = 2.29 mm3) compared to 1.21 ± 1.19 mm3 (minimum =
0.12 mm3) for those lesions only detected with MEMRI. These
results establish MEMRI as a more sensitive method for detection of
early pretumoral MB lesions in the Ptch1-CKO mice.
The long (2-hour) acquisition time required for the high-resolution
(100-μm) MEMRI protocol could become a limitation for future
imaging studies with large cohorts of mice. To address this issue, a
high-throughput T1w MEMRI protocol was implemented, with
lower spatial resolution (150 μm) but a significantly reduced
acquisition time of 15 minutes (Figure 4). Comparing images from
the same Ptch1-CKO mice, both the high-resolution and the high-
throughput MEMRI protocols allowed visualization of advanced-
stage tumors (Figure 4A, N = 12) and early pretumoral lesions
(Figure 4B, N = 16). Although images acquired with the high-
Figure 2. MEMRI allowed detection of early-stage MB lesions in Ptch1-CKO mice. Axial (A and B) and sagittal (C and D) MEMRI images
(dashed lines on A and B show the approximate location of the sagittal sections shown in C and D, respectively) revealed multiple
hypointense areas (yellow arrowheads) in the cerebella of Ptch1-CKO mice (B and D) compared to wild-type controls (A and C) at 2 to 3
weeks of age. Matched sagittal H&E sections (E and F) demonstrated accurate histologic correlation between areas of negative contrast
in MEMRI (D; yellow arrowheads) and early pretumoral lesions (F; black arrowheads). Representative 3D volume renderings fromMEMRI
data demonstrate distinct patterns of Cb lesions seen in individual Ptch1-CKOmice at 2 to 3 weeks of age. These early pretumoral lesions
were detected as unilateral, bilateral, and multiple (separated lesions shown in different colors; see Supplemental Video 1 for more
detailed visualization), as demonstrated in G. Scale bars, 1 mm.
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resolution, this effect did not have a significant impact on lesion
detectability and could be corrected by post-processing. To further
investigate the differences between the two MEMRI protocols,
quantitative volumetric analysis of MB lesions was performed in a
group of P21 mice (N = 7). All pretumoral lesions that were detected
at 100 μm were also detected at 150 μm. The calculated total average
lesion volume was 6.7 ± 3.8 mm3 for the 100-μm images, compared
to 7.8 ± 4.1 mm3 for the 150-μm images. Analysis using a two-
sample paired t test revealed that there were no significant differences
in the lesion volumes measured with the two protocols (P = .13).
Taken together, these results demonstrate that the high-throughput
(150-μm) MEMRI protocol could be used for sensitive detection and
quantitative analysis of both early pretumoral lesions and advanced-
stage MB tumors in a time-efficient manner.LongitudinalMEMRI Enabled In Vivo Analysis ofMBProgression
Longitudinal in vivo imaging of mouse models is critical to analyze
growth patterns of developing tumors and for preclinical therapeutic
studies. Previous studies of MB formation in Ptch1+/− heterozygous
mutant mice have generally defined early stages of MB as up to 8
weeks of age [64–66]. In this study, in vivo longitudinal MEMRI and
volumetric analyses were used to analyze MB progression in Ptch1-
CKO mice starting from pretumoral lesions at 3 to 7 weeks through
advanced tumor stages at 13 to 20 weeks (Figure 5, N = 21).
Specifically, one group of mice was imaged starting at 3 weeks (N =
14), while a second group was begun at a somewhat later stage
between 5 and 7 weeks (N = 7). In both groups, pretumoral lesions
were detected in each mouse at the initial time point. The average size
of detected lesions at 3 weeks (N = 14) was 6.24 ± 5.44 mm3 (min =
0.57, max = 15.8) and that at 5 to 7 weeks (N = 7) was 8.56 ± 6.05mm3
Figure 3.MEMRI was more sensitive for detecting early-stage MB than conventional T2w MRI. Representative examples are shown for
wild-type (A, B, E, and F) and Ptch1-CKO mice (C, D, G, and H) scanned with both non-contrast T2w RARE (left panels; A, C, E, and G) and
post-contrast T1wMEMRI sequences (right panels; B, D, F, and H). These images show improved tissue contrast in MEMRI compared to
RARE images and show higher sensitivity for visualization of tumor tissue (*) using MEMRI (D) compared to RARE (C), especially for
detection of early pretumoral lesions with MEMRI (H, arrowheads), which could not be detected with RARE (G). Scale bars, 1 mm.
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difference in the lesion size between the early imaging time points at 3
and 5 to 7 weeks (P = .4). Over time, the pretumoral lesions progressed
and formed MBs in most mice (Figures 5 and 6, A and B; N = 16/21,
76%), while in some mice the lesions actually regressed (Figure 6C;
N = 5/21, 24%).
Both tumor growth and regression were variable between
individual Ptch1-CKO mice. Among the mice in which all lesions
regressed (N = 5), the average lesion volume at the initial time point
was 4.33 ± 4.63 mm3 (min = 1.11, max = 12.5) and most had no
detectable lesion by 20 weeks (N = 4/5), while one took 26 weeks toregress below detectability. In the mice with tumors that progressed
(N = 16), the average lesion size was 7.9 ± 5.8 mm3 (min = 0.50,
max = 16.3), and similarly, there was significant variability in the
growth patterns of MBs in the progressing mice (N = 16). At the
early stages (3-7 weeks), most Ptch1-CKO had pretumoral lesions
that were distributed across a relatively wide region of the Cb
(Figures 2, 5, and 6), while at more advanced stages tumor growth
was predominantly in one region, showing that many of the pretumoral
lesions did not develop or were delayed in their progression (Figure 5).
Together with the data on the regressing lesions, these results strongly
suggest that although pretumoral lesions have the capacity to develop
Figure 4.MEMRI detection of advanced and early MB lesions with both high-throughput and high-resolution protocols. MEMRI images of
Ptch1-CKO mice demonstrated that both advanced-stage tumors (A) and early pretumoral lesions (B, arrowheads) were detected with
either the high-resolution (100 μm; 2 hours) or high-throughput (150 μm; 15minutes) sequences. High-throughput images were improved
by resampling the 150-μm images to 100 μm in post-processing (right panels). Scale bars, 1 mm.
Figure 5. In vivo longitudinal MEMRI enabled imaging tumor progression from early to advanced stages. Axial MEMRI images (A) and 3D
volume renderings (B) of a representative individual Ptch1-CKO mouse at sequential time points (3-18 weeks) demonstrate the feasibility
of longitudinal imaging using MEMRI. Note also that bilateral pretumoral lesions were observed at early time points (arrowheads), but at
later times, only one area exponentially progressed to an advanced MB (*). Representative examples of an axial MEMRI and 3D rendering
of a control mouse are shown at the first time point as a reference. Scale bars, 1 mm.
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Figure 6. Longitudinal MEMRI revealed variability in MB tumor growth patterns. 3D renderings from longitudinal MEMRI images of
representative Ptch1-CKO mice showed a range of MB progression rates from fast (A) to slow (B). In each panel, the segmented MB
lesions are shown in color within the whole brain (left) and separately (right). Several examples of early lesions that regressed below
detectability with MEMRI were also observed (C; N = 5/21). Quantitative analysis of MB lesion volume (D) demonstrated the distinct
growth rate patterns of the mice shown in A and B and also showed excellent fit to an exponential growth model, plotted in semi-log
format (E). To compare MB growth rates betweenmice, lesion volumes were normalized to their initial volumes and again plotted in semi-
log format (F; N = 16), demonstrating the variability observed in MB growth rates in the Ptch1-CKO mouse model. Dashed red line
represents the mean Td = 4.3 weeks. Scale bar in A, 2 mm.
Table 1. There Is No Clear Relationship between Tumor Growth Rate and Degree of Differentiation
in Ptch1-CKO MBs.
Mouse
ID
Td
(Weeks)
Initial Volume
(mm3)/[Weeks]
End Volume
(mm3)/[Weeks]
Differentiation
Index
1 9.9 14.7 [3] 36.4 [15] +++
2 6.1 0.5 [5] 3.3 [20] −
3 5.9 6.2 [3] 49.8 [20] +++
4 5.3 0.6 [3] 4.7 [15] +++
5 5.3 4.2 [3] 14.4 [13] +++
6 3.5 12.9 [3] 171.5 [20] –
7 3.2 0.6 [3] 11.9 [13] +++
8 2.9 15.8 [3] 75.5 [15] +
9 2.9 3.9 [3] 184.6 [20] –
10 2.4 6.7 [7] 87.6 [17] +++
11 2.1 16.3 [5] 239.6 [14] –
12 1.8 11.3 [7] 98.9 [17] +++
(−) 0 to 5%; (+) 5% to 25%; (++) 25% to 50%; (+++) N50% (see Methods section).
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studies [64,66,67].
Interestingly, we noticed significant differences in growth rates
between MBs that progressed (Figure 6, A, B, and D; N = 16). To
quantify tumor growth patterns, the lesion/tumor volumes were
measured at each time point and fitted to an exponential growth model,
given in Eqs. (1) and (2), for each mouse (Figure 6, D and E ).
Regression analysis showed an excellent fit of the volumetric data to the
model (R2 N 0.9 in all cases; mean ± SD = 0.96 ± 0.04). Td was highly
variable, ranging between 1.8 and 9.9 weeks, with a mean value of 4.29 ±
2.33 weeks. No obvious correlation between Td and tumor volume was
observed (Table 1). The variability in MB growth rates between
individual Ptch1-CKO mice may potentially be related to molecular
differences, such as distinct secondary mutations and epigenetic
alterations. Although molecular profiling (e.g., RNA-seq) is beyond the
scope of this study, MEMRI will be a useful tool to segregate tumors for
such analyses based on their growth rates in future studies.
Histopathologic Analysis Showed Variable Levels of Proliferation,
Differentiation, and Apoptosis in Ptch1-CKO Mice
MBs are known to show a range of histologic features, which have
been partly correlated with age of tumor onset and clinical outcomesin patients. For most SHH-MBs, the presence of either a more classic
(little differentiation) or nodular/desmoplastic (extensive differentia-
tion) histologic phenotype has been described [68,69]. To investigate
SHH-MB tumor cytoarchitecture and its possible relationship to
tumor growth rates in Ptch1-CKO mice, histologic analyses were
1002 MEMRI analysis of mouse medulloblastoma Suero-Abreu et al. Neoplasia Vol. 16, No. 12, 2014performed on a subset of MBs from the longitudinal MEMRI
analysis. Tumors were harvested to obtain a range of advanced stages
between 13 and 20 weeks and analyzed using IHC for Ki67 (red) and
p27 (green) as markers of proliferation and neuronal differentiation,
respectively (Figure 7; N = 12). MB tumors studied showed two
distinct patterns: one in which expression of Ki67 was dominant,
interspersed with scattered differentiated p27-expressing cells,
consistent with classic SHH-MB (Figure 7, A, C, E, G, and I ), andFigure 7. IHC analysis of MB tumors in Ptch1-CKOmice. MB tumors w
and differentiation, respectively (N = 12). DAB staining for Ki67 at low
presence of multiple Ki67-negative areas in some tumors (B and D) bu
location of C and D on A and B, respectively.) Within the same two tu
staining revealed that the Ki67-negative areas (F) were regions of diff
with uniform Ki67 expression (E) had scattered p27-expressing cells (
and B; 50 μm in C to J.a second biphasic pattern in which p27 expression was dominant and
clustered in multiple isolated regions surrounded by proliferating
Ki67-expressing cells (Figure 7, B, D, F, H, and J ). Qualitative and
semi-quantitative analyses of the histologic phenotypes of the Ptch1-
CKO MBs showed that there was variability in the presence and
degree of the differentiated regions within individual tumors and that
there was no clear correlation between the profiles of differentiation
and the measured Td (Table 1).ere analyzed using IHC for Ki67 and p27, as markers of proliferation
(×3; A and B) and high (×20; C and D) magnification showed the
t in not others (A and C). (Note: the red boxes show the approximate
mors, Ki67 (red; E and F)/p27 (green; G and H) double fluorescent
erentiation with high p27-expression (H and J). Conversely, tumors
G) mixed among the Ki67-expressing cells (I). Scale bars, 1 mm in A
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igenic potential among lesions in the Ptch1-CKO mice, IHC was
used to analyze pretumoral lesions at 3 weeks of age (N = 8 lesions in
four mice) and lesions that were not progressing in 13- to 15-week-
old tumor-bearing mice (N = 7 lesions in three mice). Sections were
stained with H&E for morphology, Ki67 for proliferation, p27 for
differentiation, and TUNEL for apoptosis (Figure 8). At 3 weeks, the
pretumoral lesions all showed areas of differentiation based on p27-
expressing cells, with a majority of Ki67 cells on the outer surface of
the lesions (Figure 8, A–D). Most of the early pretumoral lesions
showed low levels of TUNEL staining (N = 5/8 in three mice;
Figure 8B), but some showed higher TUNEL staining (N = 3/8 in
one mouse; Figure 8D). In individual mice at 13 to 15 weeks of age,
tumors and smaller lesions that were not progressing (confirmed by
MEMRI) were examined. The tumors (N = 3) had doubling times
that ranged from 3.2 to 5.3 weeks, and all had the more differentiated
p27/Ki67-expression patterns, as well as a uniform distribution of
TUNEL-positive cells throughout the tumors (Figure 8, E and I ).
The smaller lesions that were not progressing (N = 7) showed
dominant Ki67 expression with scattered differentiated p27-
expressing cells and lower levels of TUNEL, compared to the tumors
(Figure 8, F–H and J ). Interestingly, in both the early pretumoral
and later non-progressing lesions, p27-expressing cells were also
observed in the molecular layer, suggesting that some cells withinFigure 8. IHC analysis of early pretumoral and later non-progressing
(PTL) in two different 3-week-old Ptch1-CKOmice (A and B and C and
and the approximate locations (yellow boxes) of the immunofluoresce
(white) and the overlay of all three stains. Examples are also provided f
13-week-old (I and J) Ptch1-CKOmice. Dashed lines demarcate the PT
and internal granule layer (IGL). Early PTLs (B and D), tumors (E and I)
levels of Ki67, with variable p27 and TUNEL staining. p27 expression
compared to non-progressing lesions. Notably, sections of both PTLs
ML between the lesion and the internal granule layer (yellow arrows). M
mm in A and C; 50 μm in B, D, and E–J.these lesions may still be able to undergo differentiation and
migration but at a later stage than normal developing granule cells.
Taken together, these results indicate that cells within the early
pretumoral and later non-progressing lesions maintain a proliferative
potential as well as an ability to differentiate and undergo apoptosis
but have not yet undergone the complete malignant transformation
necessary to become tumors [66].
Discussion
Tumorigenesis is a multistep process in which initiating mutations
may lead to pretumoral stages that could further advance to
malignancy once exposed to additional oncogenic stimuli. Compar-
ing these early stages to advanced tumors can help determine which
mutations are required for early cellular transformation and which
mutations drive tumor progression. However, such studies can be
challenging in mouse models of brain tumors such as MB since the
early tumor stages are asymptomatic and tumor onset and progression
can be highly variable within individual mice and among distinct
preclinical models. In this study, we demonstrated the utility and
optimization of both high-resolution and high-throughput in vivo
MEMRI protocols to image MB progression noninvasively over a
wide range of tumor stages. Furthermore, our results demonstrated
that MEMRI provides an effective and sensitive method for the early
detection and growth rate characterization of MBs in mouse models.lesions. Cerebellar sections show examples of pretumoral lesions
D). H&E-stained sections (A and C) show the cerebellar morphology
nt sections (B and D) stained for Ki67 (red), p27 (green), and TUNEL
or tumors and non-progressing lesions (*) in 15-week-old (E–H) and
Ls and non-progressing lesions, as well as the molecular layer (ML)
, and lesions that were not progressing (F–H and J) all showed high
was more widespread and clustered in the PTLs and tumors when
and non-progressed lesions showed some p27-positive cells in the
agnification: ×1.5 (A and C) and ×20 (B, D, and E–J). Scale bars, 1
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proliferation of GCPs stimulated by excess SHH signaling. PTCH1 is a
key receptor and antagonist of the SHH signaling pathway and some
Ptch1+/− heterozygous mutant mice develop MB [24]. As a result,
Ptch1+/− mice have been used extensively to analyze the effects of
additional mutations in tumor suppressor/enhancer genes on MB
progression [65,66,70,71]. However, these studies have been hindered
by low tumor incidence (15-20%) and an unpredictable time of tumor
onset in these mice (between 6 and 12 months). To overcome these
limitations, several lines of conditional mouse models have also been
generated using different Cre-driver lines to inactivate both alleles of the
Ptch1 gene, often in the majority of GCPs or cerebellar ventricular zone
cells, and to thereby induce early global MB-like growth [25,29,30]. In
the current study, we used a Ptch1-CKO mouse model using the
Ptf1a-Cre driver [55] that deletes Ptch1 in relatively few isolated
Ptf1a-expressing GCPs mainly in the anterior embryonic Cb [72]
(Raju, in preparation). Our results demonstrate that these Ptch1-CKO
mice constitute an excellent model system to study early stages of
sporadic SHH-MB tumorigenesis.
Lacking in previous studies of mouse MB models has been an
effective noninvasive means of detecting and monitoring early stages of
MB progression in vivo. Such a method would enable investigations of
growth patterns from early stages of tumor formation, allowing
comparisons of different factors that mediate MB tumor progression
and/or regression. Importantly, we demonstrated that MEMRI is a
highly sensitive approach for imaging MB progression, from early
pretumoral lesions to advanced tumor stages. This is a significant
advance over conventional MRI methods, allowing noninvasive
imaging and in vivo analysis of very early stages of tumorigenesis.
Furthermore, our results showed the feasibility of longitudinal MEMRI
and the ability to noninvasively follow the progression of individual
MBs from early to advanced symptomatic stages. Previous studies using
histology have described the presence of early pretumoral lesions in
Ptch1+/− mice [25,64,65,73] and in other mouse MB models [74,75].
Additionally, a number of studies have suggested that some of these
pretumoral lesions can give rise to MB and that specific oncogenic
events can increase their tumorigenic capacity [66,67]. However, to our
knowledge, this is the first report that demonstrates the in vivo detection
and longitudinal imaging of individual pretumoral MB lesions as they
progress to advanced tumors.
3D renderings of the longitudinal MEMRI data sets enabled a
comprehensive visualization of the morphology of early to advanced
lesions. They also provided insight into their dynamic development
and showed that they can have different fates. In addition, 3D
volumetric studies allowed quantitative analysis of tumor growth
rates. In the current study, we found that a simple exponential growth
model provided an excellent fit to the data on tumor progression,
which was dominated by the larger volumes at advanced stages. A
more complex model would be required to describe early MB
progression and regression to account for the balance between cell
proliferation, differentiation, and apoptosis at the early stages. Our
analysis of tumor progression highlighted the presence of different
tumor growth patterns in individual Ptch1-CKO mice. This variation
of growth rates seen within the population of MBs likely explains
differences in the onset time of symptoms in Ptch1-CKO mice and
could potentially correlate to underlying molecular signatures among
tumors. The variability in tumor progression seen in this and other
mouse tumor models also highlights the need for in vivo imaging
methods to be included in preclinical studies of therapeutic agents,allowing a more accurate stratification of treatment cohorts based on
tumor stage and growth characteristics rather than age or the presence
of symptoms. The ability of MRI to quantify changes in growth rates
in other types of brain tumors has previously been demonstrated to be
useful for preclinical assessment of therapeutic response
[41,62,76,77].
Although no obvious neurotoxicity was observed in the current
study, it is relevant to mention that at high doses, Mn is known to
produce acute and chronic toxic effects [78–80]. However, MEMRI
has been extensively used as an imaging tool in multiple
neuroimaging studies at similar or even higher doses than the ones
in this study without significant toxicity [46]. In this study, repeated
MRI sessions and Mn injections were conducted over a period of
weeks to months to track tumor progression. This was well tolerated
by the mice at different ages, even as tumors were developing and
mice became symptomatic. It should be also noted that studies
assessing acute toxic effects of Mn are mostly performed with repeated
(20-30) injections in shorter intervals of 24 to 48 hours [79], while in
this study injections and subsequent MRI sessions were separated by
intervals of at least 2 to 3 weeks. The lengthened period between
injections allows the Mn to clear from neural tissues and likely further
limits its acute toxicity. Several studies have reported the implemen-
tation of fractionated Mn schedules to maximize contrast in long-
term MEMRI studies while reducing toxicity [80,81], an approach
that might be worth investigating for future implementation of
MEMRI in studies of MB progression.
Taken together, the in vivo MEMRI method described in this
paper provides a unique noninvasive approach for the early detection
and characterization of SHH-MBs in Ptch1-CKO mice that can be
applied to other MB models and other types of Cb tumors. Similar
MEMRI methods may also be useful for other brain regions and brain
tumor models such as gliomas, relying on negative contrast between
enhancing normal brain and non-enhancing tumors for detection. In
the future, MEMRI could be combined with other MRI protocols,
such as gadolinium-enhanced imaging to assess BBB permeability,
dynamic perfusion MRI to study tumor vasculature, or diffusion MRI
to examine tissue microstructural changes. These protocols have been
used in several clinical reports on MBs, but so far the imaging has
been limited to advanced heterogeneous tumors where the results
have been variable and still have no clear correlation with pathologic
subtype or prognosis [37–39,82,83].
MEMRI could be used in future studies to monitor pretumoral
MB lesions and to guide molecular and genetic expression analyses in
a stage-dependent manner. Such studies could aid in the temporal
and spatial characterization of initiating events for MB formation and
lead to greater insights into the relevant changes that distinguish the
different tumor stages. Ultimately, as the preclinical models of the
four distinct MB subgroups become further refined and additional
subtype-specific models emerge, the imaging methods presented in
this study could serve as the basis for their characterization. This
should enable a better stratification of cohorts in future preclinical
therapeutic studies targeted to molecular alterations specific to each
MB subgroup.
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